Skip to main content

Bionovate Technologies picks up semanticom for international PR

Written by Customer Service on . Posted in Public Companies.

CHAM, Switzerland and BERLIN, Oct. 17, 2020 (GLOBE NEWSWIRE) — The Berlin public relations agency wins the business with international PR and strategic corporate communications of the medical device company Bionovate Technologies Corp. The shares of the company are traded on the Nasdaq OTC (OTCPK:BIIO).Bionovate Technologies Corp. focuses on investments and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to your smartphone. With strong emphasis on digital transformation, the company intends to build an FDA-approved ecosystem of medical devices, biosensors and mobile applications to turn tests that were previously only done in physical labs into tests that can be carried through by anyone with a mobile device. Innovations in these fields are transforming some of the most promising, high-growth-opportunity segments in the medical device market worldwide.Thanks to a recently executed agreement, Bionovate will hold shares in the German health tech start up Digital Diagnostics AG, which is currently developing a promising rapid corona antigen test and will shortly launch it to the markets.Aleksandar Vucak, CEO of Bionovate: “semanticom has recognized expertise in the positioning and popular explanation of new technologies and has broad experience in international public relations for start-ups. That’s why we chose the Berlin agency.”Bionovate Technologies Corp.
Gewerbestr. 10
6330 Cham, Switzerlandpress contact
Thomas Huber
semanticom GmbH
+49 30 275 80 81 11
bionovate-pr@semanticom.eu

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.